Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants

NCT ID: NCT00192335

Last Updated: 2007-11-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 890 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-07-31
• Study Completion Date: 2005-02-28

Brief Summary

• Primary objective is to demonstrate equivalent immunogeniticity of CAIV-T and FluMist
• Secondary objective of this study is to assess the safety and tolerability of CAIV-T compared to FluMist

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

1

CAIVT-The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).

Group Type: ACTIVE_COMPARATOR

CAIV-T

Intervention Type: BIOLOGICAL

CAIVT

Intervention Type: BIOLOGICAL

The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).

2

FluMist- The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).

Group Type: ACTIVE_COMPARATOR

FluMist

Intervention Type: BIOLOGICAL

The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).

Interventions

CAIV-T

Intervention Type: BIOLOGICAL

CAIVT

The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).

Intervention Type: BIOLOGICAL

FluMist

The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Age 5 through 49 years (not yet reached their 50th birthday);
• In general good health;
• Individual or parent/guardian available by telephone;
• Ability of the participant or parent/guardian to understand and comply with the requirements of the protocol; and
• Written informed consent and HIPAA authorization obtained from the participant's parent or legal guardian or written informed consent and HIPAA authorization obtained from the participant.

Exclusion Criteria

• History of hypersensitivity to any component of FluMist or CAIV-T, including egg or egg products;
• History of hypersensitivity to gentamicin;
• Any known immunosuppressive condition or immune deficiency disease (including HIV infection), or ongoing receipt of any immunosuppressive therapy;
• Household contact who is immunocompromised (participants should also avoid close contact with other immunocompromised individuals for at least 21 days);
• History of chronic underlying medical conditions such as chronic disorders of the cardiovascular and pulmonary systems, chronic metabolic diseases (including diabetes), renal dysfunction, or hemoglobinopathies;
• History of Guillain-Barré syndrome;
• History of asthma or reactive airways disease;
• For children age 5 through 8 years, receipt of prior influenza vaccination;
• Acute febrile (>100.0°F oral) and/or respiratory illness within the 72 hours prior to enrollment;
• For participants under the age of 18, use of aspirin or aspirin containing products in the 30 days prior to enrollment or anticipated use during the study;
• Administration of any live vaccine within 30 days prior to enrollment or if receipt of another live vaccine is expected within 30 days of the vaccination in this study;
• Administration of any inactivated vaccine within two weeks prior to enrollment or if receipt of another inactivated vaccine is expected within two weeks of the vaccination in this study;
• Pregnancy or, in biologically capable women (e.g., menses within the last year), not willing to agree to acceptable birth control for 90 days after enrolling into the study (for those biologically capable, a urine pregnancy test must be performed on the day of vaccination with a negative result);
• Breastfeeding or lactating women;
• Participation in another investigational trial or administration of any investigational drug within 30 days prior to enrollment or during this study;
• Receipt of any blood product within 90 days prior to vaccination or expected receipt within the study duration;
• Employees of the research center, any individuals involved with the conduct of the study, or any family member of such individuals; and
• Any condition that in the opinion of the investigator would interfere with the interpretation or evaluation of the vaccine.

• Minimum Eligible Age: 5 Years
• Maximum Eligible Age: 49 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

MedImmune LLC

INDUSTRY

Sponsor Role: lead

Principal Investigators

Luis Angles, MD

Role: PRINCIPAL_INVESTIGATOR

Heart of America Research Institute

Locations

Heart of America Research Institute

Shawnee Mission, Kansas, United States

Kentucky Pediatric/Adult Research, Inc.

Bardstown, Kentucky, United States

R/D Clinical Research, Inc.

Lake Jackson, Texas, United States

Countries

United States

Other Identifiers

MI-CP112

Identifier Type: -

Identifier Source: org_study_id